Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 1.7% – What’s Next?

Shares of Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) were down 1.7% during mid-day trading on Tuesday . The stock traded as low as $12.78 and last traded at $12.98. Approximately 33,942 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 852,132 shares. The stock had previously closed at $13.20.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Quoin Pharmaceuticals in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Quoin Pharmaceuticals currently has an average rating of “Sell”.

Quoin Pharmaceuticals Stock Performance

The company has a 50 day moving average of $9.38 and a two-hundred day moving average of $8.37. The stock has a market cap of $7.66 million, a PE ratio of -0.31 and a beta of 1.66.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($6.28) earnings per share for the quarter, beating the consensus estimate of ($6.83) by $0.55. As a group, equities research analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -2.05 EPS for the current year.

Insider Buying and Selling at Quoin Pharmaceuticals

In other news, Director Dennis Langer acquired 15,152 shares of the business’s stock in a transaction on Tuesday, October 14th. The stock was bought at an average cost of $8.49 per share, for a total transaction of $128,640.48. Following the purchase, the director owned 15,153 shares in the company, valued at approximately $128,648.97. This represents a 1,515,200.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 13.46% of the stock is currently owned by corporate insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.